179 related articles for article (PubMed ID: 26113237)
1. Inhalable Clarithromycin Microparticles for Treatment of Respiratory Infections.
Dimer F; de Souza Carvalho-Wodarz C; Haupenthal J; Hartmann R; Lehr CM
Pharm Res; 2015 Dec; 32(12):3850-61. PubMed ID: 26113237
[TBL] [Abstract][Full Text] [Related]
2. Development of an inhaled controlled release voriconazole dry powder formulation for the treatment of respiratory fungal infection.
Arora S; Haghi M; Loo CY; Traini D; Young PM; Jain S
Mol Pharm; 2015 Jun; 12(6):2001-9. PubMed ID: 25923171
[TBL] [Abstract][Full Text] [Related]
3. Repurposing ebselen as an inhalable dry powder to treat respiratory tract infections.
Saha T; Lyons N; Yue Yung DB; Quiñones-Mateu ME; Pletzer D; Das SC
Eur J Pharm Biopharm; 2024 Feb; 195():114170. PubMed ID: 38128743
[TBL] [Abstract][Full Text] [Related]
4. Aerodynamic properties, solubility and in vitro antibacterial efficacy of dry powders prepared by spray drying: Clarithromycin versus its hydrochloride salt.
Manniello MD; Del Gaudio P; Porta A; Aquino RP; Russo P
Eur J Pharm Biopharm; 2016 Jul; 104():1-6. PubMed ID: 27106605
[TBL] [Abstract][Full Text] [Related]
5. Novel Inhaled Combination Powder Containing Amorphous Colistin and Crystalline Rifapentine with Enhanced Antimicrobial Activities against Planktonic Cells and Biofilm of Pseudomonas aeruginosa for Respiratory Infections.
Zhou QT; Sun SP; Chan JG; Wang P; Barraud N; Rice SA; Wang J; Li J; Chan HK
Mol Pharm; 2015 Aug; 12(8):2594-603. PubMed ID: 25423590
[TBL] [Abstract][Full Text] [Related]
6. Preparation and Characterization of Doripenem-Loaded Microparticles for Pulmonary Delivery.
Yildiz-Peköz A; Akbal O; Tekarslan SH; Sagirli AO; Mulazimoglu L; Morina D; Cevher E
J Aerosol Med Pulm Drug Deliv; 2018 Dec; 31(6):347-357. PubMed ID: 29877747
[No Abstract] [Full Text] [Related]
7. Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols.
Park CW; Li X; Vogt FG; Hayes D; Zwischenberger JB; Park ES; Mansour HM
Int J Pharm; 2013 Oct; 455(1-2):374-92. PubMed ID: 23820131
[TBL] [Abstract][Full Text] [Related]
8. Physico-Chemical Properties, Aerosolization and Dissolution of Co-Spray Dried Azithromycin Particles with L-Leucine for Inhalation.
Mangal S; Nie H; Xu R; Guo R; Cavallaro A; Zemlyanov D; Zhou QT
Pharm Res; 2018 Jan; 35(2):28. PubMed ID: 29374368
[TBL] [Abstract][Full Text] [Related]
9. A new Pharmaceutical Aerosol Deposition Device on Cell Cultures (PADDOCC) to evaluate pulmonary drug absorption for metered dose dry powder formulations.
Hein S; Bur M; Schaefer UF; Lehr CM
Eur J Pharm Biopharm; 2011 Jan; 77(1):132-8. PubMed ID: 20951200
[TBL] [Abstract][Full Text] [Related]
10. Highly respirable dry powder inhalable formulation of voriconazole with enhanced pulmonary bioavailability.
Arora S; Haghi M; Young PM; Kappl M; Traini D; Jain S
Expert Opin Drug Deliv; 2016; 13(2):183-93. PubMed ID: 26609733
[TBL] [Abstract][Full Text] [Related]
11. Inhalable liposomal powder formulations for co-delivery of synergistic ciprofloxacin and colistin against multi-drug resistant gram-negative lung infections.
Yu S; Wang S; Zou P; Chai G; Lin YW; Velkov T; Li J; Pan W; Zhou QT
Int J Pharm; 2020 Feb; 575():118915. PubMed ID: 31816354
[TBL] [Abstract][Full Text] [Related]
12. Carrier-free combination for dry powder inhalation of antibiotics in the treatment of lung infections in cystic fibrosis.
Pilcer G; De Bueger V; Traina K; Traore H; Sebti T; Vanderbist F; Amighi K
Int J Pharm; 2013 Jul; 451(1-2):112-20. PubMed ID: 23643509
[TBL] [Abstract][Full Text] [Related]
13. Development and Evaluation of Chitosan Microparticles Based Dry Powder Inhalation Formulations of Rifampicin and Rifabutin.
Pai RV; Jain RR; Bannalikar AS; Menon MD
J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):179-95. PubMed ID: 26406162
[TBL] [Abstract][Full Text] [Related]
14. Design, characterization, and aerosol dispersion performance modeling of advanced co-spray dried antibiotics with mannitol as respirable microparticles/nanoparticles for targeted pulmonary delivery as dry powder inhalers.
Li X; Vogt FG; Hayes D; Mansour HM
J Pharm Sci; 2014 Sep; 103(9):2937-2949. PubMed ID: 24740732
[TBL] [Abstract][Full Text] [Related]
15. Development of a novel dry powder inhalation formulation for the delivery of rivastigmine hydrogen tartrate.
Simon A; Amaro MI; Cabral LM; Healy AM; de Sousa VP
Int J Pharm; 2016 Mar; 501(1-2):124-38. PubMed ID: 26836711
[TBL] [Abstract][Full Text] [Related]
16. Clarithromycin and N-acetylcysteine co-spray-dried powders for pulmonary drug delivery: A focus on drug solubility.
Manniello MD; Del Gaudio P; Aquino RP; Russo P
Int J Pharm; 2017 Nov; 533(2):463-469. PubMed ID: 28377314
[TBL] [Abstract][Full Text] [Related]
17. New co-spray-dried tobramycin nanoparticles-clarithromycin inhaled powder systems for lung infection therapy in cystic fibrosis patients.
Pilcer G; Rosière R; Traina K; Sebti T; Vanderbist F; Amighi K
J Pharm Sci; 2013 Jun; 102(6):1836-1846. PubMed ID: 23568616
[TBL] [Abstract][Full Text] [Related]
18. Immunomodulatory effects of a low-dose clarithromycin-based macrolide solution pressurised metered dose inhaler.
Haghi M; Saadat A; Zhu B; Colombo G; King G; Young PM; Traini D
Pharm Res; 2015 Jun; 32(6):2144-53. PubMed ID: 25537341
[TBL] [Abstract][Full Text] [Related]
19. Steroid-decorated antibiotic microparticles for inhaled anti-infective therapy.
Lee SH; Teo J; Heng D; Zhao Y; Ng WK; Chan HK; Tan RB
J Pharm Sci; 2014 Apr; 103(4):1115-25. PubMed ID: 24510431
[TBL] [Abstract][Full Text] [Related]
20. Drug transport across pulmonary epithelial cell monolayers: effects of particle size, apical liquid volume, and deposition technique.
Bur M; Huwer H; Muys L; Lehr CM
J Aerosol Med Pulm Drug Deliv; 2010 Jun; 23(3):119-27. PubMed ID: 20073555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
